The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy

Basit Öğe Kaydı
dc.authoridAksoy, Ayse/0000-0001-7533-1638;
dc.contributor.authorSonmez, Fatma Mujgan
dc.contributor.authorZaman, Dilek
dc.contributor.authorAksoy, Ayse
dc.contributor.authorDeger, Orhan
dc.contributor.authorAliyazicioglu, Rezzan
dc.contributor.authorKaraguzel, Gulay
dc.contributor.authorFazlioglu, Kerim
dc.date.accessioned2025-10-24T18:09:11Z
dc.date.available2025-10-24T18:09:11Z
dc.date.issued2013
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractPurpose: Antiepileptic drugs may affect the endocrine system. We investigated the effects of valproic acid and topiramate on the levels of insulin, c-peptide and adipocytokines in pre-pubertal patients with idiopathic partial and generalized epilepsy. Methods: Forty-one children with epilepsy were included. The patients were divided into two groups (valproic acid; n = 21, topiramate; n = 20). The weight, height, body mass index and homeostasis model assessment of insulin resistance (HOMA-IR) were recorded and insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin and resistin levels were determined at 0, 6 and 12 months of therapy. Results: In the valproate group, weight and height increased significantly. Seven of 21 patients were overweight at the end of one year. Leptin was higher in the overweight subgroup. Although insulin and HOMA-IR increased (p < 0.05), none of the patients showed hyperinsulinism or IR. Resistin had decreased at the 6th and 12th months (p < 0.05). In the topiramate group, some statistically nonsignificant changes were demonstrated. Conclusion: The mechanisms behind valproate and topiramate-related weight control are still unclear, especially in children. Valproate and topiramate affect the weight, BMI, and insulin, leptin and adipocytokine levels in prepubertal children. We suggest that further studies including more patients with a long follow-up period are necessary to draw a firm conclusion regarding an association between the treatment with these drugs and the levels of leptin, insulin and adipocytokines. (C) 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
dc.description.sponsorshipKaradeniz Technical University Research Foundation [2006-114031]
dc.description.sponsorshipThis study was supported by the Karadeniz Technical University Research Foundation (Project number: 2006-114031).
dc.identifier.doi10.1016/j.seizure.2013.07.007
dc.identifier.endpage861
dc.identifier.issn1059-1311
dc.identifier.issn1532-2688
dc.identifier.issue10
dc.identifier.pmid23937963
dc.identifier.scopus2-s2.0-84888002921
dc.identifier.scopusqualityQ2
dc.identifier.startpage856
dc.identifier.urihttps://doi.org/10.1016/j.seizure.2013.07.007
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3492
dc.identifier.volume22
dc.identifier.wosWOS:000327687300008
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherW B Saunders Co Ltd
dc.relation.ispartofSeizure-European Journal Of Epilepsy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectValproate; Topiramate; Weight; Adipocytokines; Insulin; C-peptide
dc.titleThe effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu